Trials / Conditions / Systemic Juvenile Idiopathic Arthritis

Systemic Juvenile Idiopathic Arthritis

13 registered clinical trials studyying Systemic Juvenile Idiopathic Arthritis — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients NCT07517250	Novartis Pharmaceuticals	—
Unknown	Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection NCT05027373	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Phase 1
Recruiting	A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenil NCT04088396	Eli Lilly and Company	Phase 3
Completed	Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA NCT02396212	Novartis Pharmaceuticals	Phase 3
Completed	A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers W NCT02334748	Novartis Pharmaceuticals	Phase 3
Withdrawn	An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients Wi NCT01676948	Novartis Pharmaceuticals	Phase 3
Completed	Ultrasonography in Juvenile Idiopathic Arthritis NCT01304420	University of Aarhus	—
Completed	An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Activ NCT00891046	Novartis Pharmaceuticals	Phase 3
Terminated	Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthr NCT00886769	Novartis Pharmaceuticals	Phase 3
Completed	Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Sys NCT01803321	Regeneron Pharmaceuticals	Phase 1
Completed	Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) NCT00144664	Chugai Pharmaceutical	Phase 3
Completed	Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) NCT00144612	Chugai Pharmaceutical	Phase 3
Completed	Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) NCT00144599	Chugai Pharmaceutical	Phase 3